p(Man-TLR7-PDS) combination therapy is well-tolerated and induces distinct immune phenotype. C57Bl/6 mice were inoculated with 1 million C1498 cells IV (day 0). For each experiment, combination treatment was administered with 2 mg cytarabine on day 1 followed by 40 μg TLR7 equivalent of p(Man-TLR7-PDS), repeated weekly. Time between injections and number of weeks of treatment varies as described. (A-D) Combination treatment was separated by 24 hours and repeated for 3 weeks (n = 5). On day 16 (week 3), 6 hours after polymer injection, serum was collected for analysis. Serum was analyzed for changes in (A) albumin, (B) alanine transferase, (C) inflammatory mediators interferon gamma, and (D) IL-6 levels. (E) Combination treatment was separated by 24 hours and administered for 4 weeks (n = 6). On day 23, endogenous C1498–specific IgG was quantified via on-cell ELISA for surviving mice. (F-G) Combination treatment was separated by 24 hours and repeated for 3 weeks (n = 6). On day 20, blood was analyzed for (F) total CD8⁺ T cells and (G) their CD69 expression. Experiment was repeated with similar results. (H-L) Combination treatment was separated by 24 hours and repeated for 3 weeks (n = 5). On day 20, spleens were harvested and analyzed via flow cytometry relative to healthy control mice (n = 3). T-cell subsets were compared, including (H) total CD3⁺ T-cell compartment, (I) CD137 expression on total T cells, (J) fraction of T cells that are CD8⁺, and (K) PD-1 and (L) CD69 expression on CD8⁺ T cells. All data are plotted as mean ± SEM. Statistical analyses were performed using unpaired t tests (A), Pearson correlation (B), and ordinary 2-way analysis of variance with multiple comparisons (C-K). ∗P < .05; ∗∗P < .01. IL-6, interleukin-6.